Cargando…
Preclinical and Clinical Sex Differences in Antipsychotic-Induced Metabolic Disturbances: A Narrative Review of Adiposity and Glucose Metabolism
Antipsychotic (AP) medications are associated with an increased risk of developing metabolic side effects including weight gain, type 2 diabetes (T2D), dyslipidemia, and hypertension. In the majority of clinical studies, females on APs are noted to gain more weight, and are more likely to be diagnos...
Autores principales: | Castellani, Laura N., Costa-Dookhan, Kenya A., McIntyre, William B., Wright, David C., Flowers, Stephanie A., Hahn, Margaret K., Ward, Kristen M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6760310/ https://www.ncbi.nlm.nih.gov/pubmed/31555747 http://dx.doi.org/10.20900/jpbs.20190013 |
Ejemplares similares
-
S89. INVESTIGATING METABOLIC DYSFUNCTION AND METABOLOMIC PROFILE CHANGES IN ANTIPSYCHOTIC NAIVE PATIENTS
por: Costa-Dookhan, Kenya, et al.
Publicado: (2020) -
Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia
por: MacKenzie, Nicole E., et al.
Publicado: (2018) -
Metformin for the treatment of antipsychotic-induced metabolic disturbances in people with intellectual and developmental disabilities
por: Stogios, Nicolette, et al.
Publicado: (2023) -
O9.2. ANTIPSYCHOTIC DRUGS IMPAIR BRAIN GLUCOSE SENSING RESULTING IN WHOLE BODY INSULIN RESISTANCE
por: Castellani, Laura, et al.
Publicado: (2020) -
Pharmacological Interventions to Treat Antipsychotic-Induced Dyslipidemia in Schizophrenia Patients: A Systematic Review and Meta Analysis
por: Kanagasundaram, Pruntha, et al.
Publicado: (2021)